by Richard Daverman, PhD
December 10, 2012 -- The Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Science (CAS), will collaborate with MRC Technology, a UK-based technology transfer and early development institute. SIBCB will contribute potential new drug targets, on which MRC will build IP and conduct early-stage research. MRC describes itself as a liaison between university-level researchers and pharmas that are looking for lead drug candidates. More details....
